Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies.
Antoine HollebecqueStefania SalvagniRuth PlummerPatricia NiccoliJaume CapdevilaGiuseppe CuriglianoVictor MorenoFilippo de BraudSonia Gonzalez de VillambrosiaPatricia Martin-RomanoEric BaudinMarina AriasJuan de AlvaroJosep L Parra-PalauTania Sánchez-PérezIda AronchikEllen H FilvaroffManisha LambaZariana NikolovaJohann S de BonoPublished in: Cancer (2022)
The safety profile of CC-90011 suggested that its reversible mechanism of action may provide an advantage over other irreversible LSD1 inhibitors. The favorable tolerability profile, clinical activity, durable responses, and once-per-week dosing support further exploration of CC-90011 as monotherapy and in combination with other treatments for patients with advanced solid tumors and other malignancies.